Scientific Committee

A senior advisory board & A Scientific Committee formed by renowned experts and managers with international experience in a large spectrum of complementary fields


Laura Bossi currently acts as a senior strategic consultant to various companies in the life science area, mainly focusing on neurological and psychiatric disorders. Her main positions include: Chief Medical Officer, Director of Preclinical & Clinical Development (Pharnext, 2008-2009, 2011), Chief Medical Officer, Director of Preclinical & Clinical Development (Faust Pharmaceuticals, 2004-2008), Chief Executive Officer and founder (Elistem, 2002-2007), Chief Executive Officer and founder (Physis 1999-2006), Vice-President – Director of the C.N.S. Therapeutic Area worldwide (SANOFI Recherche 1997-1999). She has authored or co-authored 120 scientific publications and six books. She was awarded the distinction « Chevalier de la légion d’honneur » (2011).


Gilles is Board member or adviser for several Pharma and Biotech companies (GABC – Gilles Avenard Biotech Consulting) and Chief Executive Officer of G1J-IDF, a seed venture fund in Life Sciences. From 1997 to 2010, he served as Chief Operating Officer of BioAlliance Pharma SA (BIO – NYSE-EURONEXT) since he co-founded the company. From 1990 to 1997, Gilles served as Medical Director of Development in the Cassenne Laboratories division of Hoechst Marion Roussel (Sanofi-Aventis Pharma). He has also served as a physician in hemobiology and blood transfusion at the Blood Center of Pitié-Salpétrière Hospital in Paris. He is currently a member of the Biotech Working Group at LEEM and Expert for Research Tax Credit at the Research Ministry.

Norebert DEREU

Norbert holds a PhD in Chemistry from the University of Liege (since 1978). After a postdoctoral fellowship from 1978 to 1981 at Texas A&M University, he started his professional career in various positions in research at A Nattermann & GmbH Company. After the acquisition of this company by Rhone-Poulenc Santé in 1986 he joins the French Research Center in 1990. Initially he led a medicinal chemistry department within chemistry and then, after the merger with Rorer, the French medicinal chemistry department in Vitry-sur-Seine. Following the merger of Rhone-Poulenc Rorer with Hoechst Marion Roussel, he became the head of the chemistry department of Aventis France in 2000. After the merger with Sanofi in 2005, Norbert headed the Chemical Sciences department in Vitry-sur-Seine as well as the entity of fermentation and extraction/purification of natural products in Frankfurt.


Dominique graduated as a M.D. from the Claude Bernard University in Lyon in 1978. He was Professor at the Lyon Blood Center. There, he developed the Gel Test technique with Dr Lapierre. In 1987 he received a Ph.D. in Immunology and majored in Pediatrics. He became Director of the Lyon Blood Transfusion Center in 1994 and Associate Professor of Haematology and Blood Transfusion in 1997 at the Claude Bernard University. In 2001 he was selected to coordinate a European platelet immunology research programs (QLK3-CT-2001-01169 / 5th PCRD). To date Dominique has published more than 180 articles in various scientific areas in peer reviews and he is asked regularly to review articles. He has invented 15 patents and these last years has focused his research work on the role of human dendritic cells, on the platelet immunology field and on the hematopoietic stem cell transplantation.


Gilles started a career in the Pharmaceutical Industry in 1984 and worked first for 2.5 years as Study Director for nonhuman primates toxicity studies at Searle. Then Gilles moved to Pfizer and worked for 22 years as a Senior Toxicologist and Scientific Adviser. During these years, he has acquired a broad experience in the development of new molecules and in the strategy for evaluating the safety and adverse effects of various pharmaceutical compounds. In 2008, Gilles joint Tibotec/Johnson and Johnson and worked for 2 years as Senior Director Preclinical Toxicology, actively participating in the safety evaluation of new anti-viral compounds. As an expert in Drug Development and Toxicology, he is currently working as a scientific consultant for the Pharmaceutical or Biotechnological Industry or for CROs.